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Background: To appraise the role of volumetric modulated arc (RapidArc, RA) in the treatment of anal canal
carcinoma (ACC).
Methods: A retrospective analysis has been conducted on 36 patients treated with RA since 2009 comparing
outcome against a group of 28 patients treated with conformal therapy (CRT). RA treatments were prescribed with
SIB technique with 59.4 Gy to the primary tumor and nodes and 49.5 Gy to the elective nodes. CRT was
sequentially delivered with 45 Gy to the pelvic target and a boost of 14.4 Gy to the primary tumor.
Results: Median age of patients was 65 yrs for RA (59 yrs for CRT); 90% had Stage II-III (93% in the CRT group). No
statistically significant differences were observed concerning survival or control. 5 yrs disease specific survival was
85.7% and 81.2%, loco-regional control was of 78.1% and 82.1% for RA and CRT respectively. RA treatments lead to
lower incidence of higher grade of toxicity events (all retrospectively retrieved from charts as worse events). Grade
2–3 toxicity, compared to CRT, reduced from 89% to 68% for GI, from 39% to 33% for GU and from 82% to 75% for
the skin. Late toxicity was as follows: 5/36 (14%) and 3/36 (8%) patients had G1 or G2 GI toxicity in the RA group
(1/28 (4%) and 4/28 (14%) in the CRT group). GU late toxicity was observed only in 4/28 (14%) patients of the CRT
group: 3/28 (11%) had G2 and 1/28 (4%) had G1.
Conclusions: RA treatments of ACC patients proved to be equally effective than CRT but it was associated to a
reduction of toxicity.
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The treatment of squamous cell carcinoma (SCC) of the
anus evolved in the last decades from the concept of
abdomino-perineal resection to the approach of definitive
pelvic radiotherapy combined with chemotherapy. The
latter is the current standard of care and provided
excellent results in term of sphincter preservation,
loco-regional control and overall survival. However, this
treatment regimen, is often associated with relevant acute
dermatological, genitourinary and gastrointestinal toxicities.* Correspondence: luca.cozzi@humanitas.it
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unless otherwise stated.From a technical point of view, the use of intensity
modulated radiation therapy (IMRT), appeared attractive
due to its potential to reduce acute and chronic treatment-
related toxicity and it was recently implemented also for
the treatment of the anal cancer. IMRT is the delivery of
non-uniform photon beams from different entry portals to
generate an highly uniform target irradiation with the
maximization of the sparing of the surrounding healthy
tissues, This method of irradiation resulted in lower rates
of acute and late grade > 3 toxicity while maintaining at
least similar outcomes in terms of local control and sur-
vival as reported in several studies [1-10].
Volumetric modulated arc therapy (VMAT), is a
method to combine rotational therapy techniques withd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and applied to a large variety of clinical indications.
RapidArc (RA) is a specific form of VMAT imple-
mented at planning and delivery level with continuous
modulation of multileaf collimator, dose rate and gantry
rotational speed dynamics. Little has been done so far in
testing its role in the radiation treatment of anal SCC.
Two planning studies [11,12], reported about a com-
parison between IMRT and RA and demonstrated the
technical feasibility of RA in terms of improved organs
at risk sparing but did not addressed any comparison
against conventional conformal therapy, the treatment
of choice in many institutes for this category of patients.
Aim of the present report is to summarize the retro-
spective clinical experience of a single institute over two
cohorts of patients treated either with conformal radio-
therapy (CRT) or with volumetric modulated arc ther-
apy. CRT, i.e. the delivery of uniform photon beams
from multiple entry portals with good homogeneity of
target irradiation but limited potential for healthy tissue
sparing, was the standard treatment of choice until 2008
for all these patients while, after its clinical introduction,
RA became the consolidated technique.
Methods
Between January 2006 and May 2013, 64 patients with
histologically confirmed anal SCC and good perform-
ance status (PS 0–1) underwent radiation therapy alone
or concurrent chemotherapy. All patients were treated
in compliance with the Helsinki Declaration. This study
is a summary of a retrospective analysis to the treatment
charts and did not required ethical approval pending
local regulations.
All patients underwent digital rectal examination, either
rigid proctoscopy or flexible sigmoidoscopy, and com-
puted tomography (CT) scans of the abdomen and
pelvis for staging. Magnetic resonance imaging and/or
endoscopic ultra sound and FDG PET-CT scan were
not routinely performed for staging. Patients were
staged according to the American Joint Committee on
Cancer (AJCC) 2006 guidelines.
Human immunodeficiency virus (HIV) and Human pap-
illoma virus (HPV) viral status and other co-morbidities
were recorded to complement the staging information.
Two Clinical Target Volumes (CTVs) were defined on
the planning CT images: CTV_boost included the gross
tumour volume (GTV) plus a margin of 10 mm to
include areas at risk of microscopic spread. These latter
were represented by the entire anal canal, the peri-anal
region and the meso-rectum. If present, positive lymph
nodes were included in the CTV-boost.
The pelvic CTV was contoured by an expansion of
10 mm around the inguinal, femoral, external iliac,
internal iliac and common iliac vessels. Muscles andbones were subtracted from the expansion. Contouring
was performed in accordance with institutional and
international guidelines [13-15]. In some patients, the
use of PET-CT imaging improved the identification of
the targets for radical dose prescription in the cases
eligible to prophylactic irradiation. Planning target
volume (PTVs) were contoured by adding an isotropic
expansion of 10 mm to the CTVs.
The small bowel, the bladder and the femoral heads as
well as the external genitals were contoured as organs at
risk. Clinical planning objectives (used as a guidance in
CRT and as optimization objectives for RA) were: V40 Gy <
50% for the bladder, V40 Gy < 30% for the bowel (defined as
the entire bowel “bag”), V40% < 25% for the genitals; V40 Gy <
25% and D1% < 50 Gy for the femoral heads (Vx Gy is the vol-
ume of a structure receiving at least x Gy while Dx% is the
dose received by at maximum x% of an organ).
All treatment plans were developed using the Varian
Eclipse planning system and dose calculation was per-
formed with the Anisotropic Analytical Algorithm with
a spatial resolution of 2.5 mm. RA plans were optimized
with the Progressive Resolution Algorithm (versions 8.9
and 10.0). All treatments were performed with photon
beams of 18 MV for CRT and of 6 MV for RA generated
by either a Varian Clinac 2100 or by a TrueBeam linear
accelerator equipped with a Millennium 120 MLC.
Conformal radiation therapy
For all patients in the CRT cohort, the treatment plan-
ning CT scans were acquired without intravenous and
oral contrast in free quiet breathing mode with a slice
thickness of 3 mm. Patients were positioned supine, with
the arms raised above the head. Immobilisation was
granted by means of legs fixations. The treatment plans
were designed and customized according to the charac-
teristics of the individual case with multiple static fields
(3–5 per plan), conformed to the target volumes with
the multileaf collimator. Dose distributions were im-
proved by using mechanical or virtual wedges. Image
guidance was performed by means of paired orthogonal
two-dimensional kilo-voltage images at the first fraction
followed by similar procedures twice per week. Patient
repositioning was performed whenever necessary.
The treatment of patients in the CRT group was per-
formed with a sequential approach with a dose prescrip-
tion of 45 Gy in 25 fractions to the pelvic PTV followed
by a boost dose of 14.4 Gy in 8 fractions to ) PTV_boost
(inclusive of eventual positive nodes). Plans were nor-
malized to the isocenter as per ICRU62 [16] specifications.
Volumetric modulated arc therapy
Starting with 2009, all anal SCC patients were treated
with VMAT RA. In this subgroup of patients, CT scans
with and without contrast intravenous and oral contrast
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thickness of 3 mm and used for treatment planning.
Patients were positioned as for the CRT group. Image
guidance for the RA group was performed by means of
Cone Beam CT imaging (CBCT) before every treatment
session. When necessary, treatment couch repositioning
was performed after automatic matching of CBCT
images to the reference planning CT, followed by manual
refining. Matching was performed on bones and, when
possible, on soft tissue structures (e.g. main blood vessels).
The RA plans were optimized for each individual patients
using 2–4 full coplanar arcs with a typical collimator
rotation in the range of 10-30° or 80-85°.
With RA, the treatment was administered with a
simultaneous integrated boost (SIB) approach. With SIB,
both primary (PTV_boost) and pelvic (PTV) target
volumes are treated simultaneously with different dose
levels as easily achievable with the use of intensity mod-
ulated beams. The dose to the primary tumor and
involved nodes was 59.4 Gy in 33 fractions (1.8 Gy per
fraction), independently of the T stage. The dose to the
elective nodal volume was 49.5 Gy in 33 fractions with
1.5 Gy per fraction. Plans were normalized to the mean
CTV_boost dose as per ICRU83 [17] recommendations.
Chemotherapy
Most of the patients received concurrent chemo-
radiotherapy CH-RT. The indication and choice of
chemotherapy regimen was left to the referring med-
ical oncologist.
Concurrent CH was given to patients with tumors
greater than 5 cm in size and/or with nodal involvement,
when KPS status was >70. The most commonly used regi-
men was fluorouracil (FU) 1000 mg/m2/day for 4 day cycles
(days 1–4 and 29–33) and mitomycin-C (MMC) 10 mg/m2
(maximum dose 20 mg) on days 1 and 29. Other regimens
used during this time period included FU 1000 mg/m2/day
for 4 day cycles (days 1–4 and 29–33) and cisplatin (cis-
diamminedichloroplatinum(II) CDDP) 75 mg/m2 (days 1,
29) or FU 1000 mg/m2/day for 4 day cycles (days 1–4
and 29–33) given alone due to other co-morbidities.
Six HIV positive cases were treated with locally
advanced anal SCC histologically confirmed and good
performance status (PS 0–1) with concomitant chemo-
radiotherapy and antiretroviral therapy. All 6 patients
were immunologically stable in antiretroviral therapy.
Evaluation
Dosimetric parameters of treatment plans were scored
by means of dose volume histograms (DVH) analysis.
This was done for all patients in the two cohorts.
Clinical evaluation during the course of treatment
was performed weekly and included laboratory tests.
Assessment of treatment response was performed, withreference to baseline conditions, at 3 and 6 months
after treatment (with CT scan and proctoscopy/sigmoi-
doscopy) and then every 3–4 months. Late follow-up
included a CT scan every 6 months while proctoscopy/
sigmoidoscopy was performed at least once per year.
For the scope of the present analysis, acute and late
toxicities were retrieved retrospectively from clinical
charts as worst toxicity reported (per each domain).
In general, toxicity assessment was performed at all
follow-up visit. Toxicity was scored using the Radiation
Therapy Oncology group (RTOG) and the Common
Terminology Criteria for Adverse Events (CTCAE)
v. 4.0 respectively. Evaluation of tumour response was
defined according to the Response Evaluation Criteria
in Solid Tumour (RECIST) v.1.1 [18].
Statistical analysis was performed by standard Kaplan-
Meier and Fisher tests per each of the two cohorts
(SPSS package, version 20.0). The Wilcoxon matched-
paired signed-rank test was applied to evaluate the level
of significance of the observed differences between the
dose-volume metrics. The threshold for statistical
significance was set at 0.05. The Mann–Whitney U test
for independent samples was applied to assess the
potential difference between the toxicity profiles.
Results
Patients and dosimetric characteristics:
Table 1 summarizes the demographic and clinical char-
acteristics of the patients. Twenty-eight patients were
treated with CRT and thirty-six with RA. Six patients
(3 per group) had HIV positive status and all concluded
the treatment receiving the entire prescription dose.
One patient in the RA group had evidence of liver
metastasis at diagnosis. CRT patients received the
prescribed treatment in 26/28 cases. One patient
interrupted the treatment after 31 fractions (acute
skin toxicity of grade 3). All RA patients completed
the prescribed treatment with the exception of one case
interrupted after 32 fractions due to acute diarrhea toxicity
(G2). Toxicity related treatment pauses longer than 3 days
were registered and reported in Table 1 with a modest
longer median duration in the CRT group.
Table 2 reports the summary of the DVH analysis for
all the patients for the various CTV, PTV and organs at
risk. Figure 1 shows the average DVH for the corre-
sponding structures comparing the two techniques
(healthy tissue in the body volume in the CT scan minus
the envelope of targets). The quantitative analysis of the
data, revealed that both techniques achieved an high
degree of target coverage in the absence of any statisti-
cally significant difference. Concerning organs at risk,
statistically significant differences were observed for
most of the structures. In more detail, the more modern
technique based on rotational intensity modulation
Table 1 Demographic and clinical characteristics
CRT RA
n % n %
Total no of patients 28 - 36 -
Age, years
Median 59 [41–80] - 65 [44–84] -
Sex
Male 9 32.1 7 19.4
Female 18 64.3 29 80.6
HIV status
Positive 3 10.7 3 8.3
Negative 24 85.7 33 91.7
HPV status
Positive 2 7.1 1 2.8
Negative 25 92.8 35 97.2
T stage
Tx 0 0 2 5.6
T1 1 3.6 1 2.8
T2 18 64.3 21 58.3
T3 6 21.4 9 25.0
T4 3 10.7 3 8.3
N stage
Nx 1 3.6 0 0
N0 12 42.9 23 63.9
N1 12 42.9 6 16.7
N2 1 3.6 2 5.6
N3 2 7.1 5 13.9
M stage
M0 28 100 35 97.2
M1 0 0 1 2.8
Stage
X 1 3.6 2 5.6
I 1 3.6 1 2.8
II 10 35.7 19 52.8
III 16 57.1 13 36.1
IV 0 0 1 2.8
Chemotherapy
FU/MMC 11 39.3 29 80.5
FU/CDDP 16 57.1 2 5.5
FU 1 3.6 0 0
None 0 0 5 13.9
Radiation therapy (33 fractions)
Prescription (Gy) 45/59.4 49.4/59.4
Duration median (days) 49 51.0
RT break >3 days 6 21 6 17
Median break (days) 10 - 7.5 -
Table 2 Summary of the DVH analysis for the CTV, PTV
and OARs for the entire cohort of patients
Parameter CRT RA
CTV PTV CTV PTV
Mean (Gy) 49.3 ± 1.3 48.8 ± 1.0 50.9 ± 0.7 50.2 ± 0.5
D1% (Gy) 60.8 ± 1.2 60.4 ± 1.1 59.7 ± 0.6 54.4 ± 1.4
D99% (Gy) 44.4 ± 0.6 43.4 ± 1.0 48.4 ± 0.6 46.9 ± 0.8
CTV_Boost PTV_Boost CTV_Boost PTV_Boost
Mean (Gy) 60.4 ± 1.1 60.2 ± 1.0 59.5 ± 0.3 59.3 ± 0.3
D1% (Gy) 61.3 ± 1.3 61.5 ± 1.3 60.6 ± 0.4 61.0 ± 0.4
D99% (Gy) 58.9 ± 0.8 57.9 ± 1.4 57.8 ± 1.6 55.5 ± 4.8
Bladder
Mean (Gy) 47.2 ± 5.6 (p = 0.02) 34.2 ± 6.6
V40 Gy (%) 86.4 ± 25.4 (p < 0.001) 33.8 ± 18.2
Bowel
Mean (Gy) 30.8 ± 9.1 26.5 ± 6.8
V40 Gy (%) 41.4 ± 27.7 (p = 0.04) 22.9 ± 9.0
Femoral heads
D1% (Gy) 51.4 ± 7.2 43.8 ± 2.6
Genitals
V40 Gy (%) 42.6 ± 24.8 (p < 0.01) 22.1 ± 10.3
Healthy tissue
Mean (Gy) 18.9 ± 4.4 (p = 0.01) 11.9 ± 1.6
V10 Gy (%) 53.6 ± 11.9 (p = 0.03) 41.4 ± 6.1
Data are reported as average values plus or minus standard deviation.
Dx%: dose received by at least x% of the volume; Vx%: volume receiving at
least x% of the dose. p values from independent samples test have been
reported only for cases with p < 0.05.
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objectives. The conventional CRT approach resulted in
a systematic failure in the fulfillment of the ideal dose-
volume objectives.
For the bladder, the constraint of V40 Gy < 50% was
improved of about 15% with RA while it was severely
violated for the CRT patients. V40 Gy < 30% for the
bowel was improved of about 8% with RA; V40% < 25%
for the genitals was slightly improved with RA while it
was almost doubled with in the CRT cohort; D1% < 50
Gy for the femoral heads safely achieved for RA and
almost for CRT.
Survival and local control
The median follow-up of the patients was: 68.5 (range:
6–93) and 19.0 (range: 7–59) months for the CRT and
RA groups respectively.
Figure 2 shows the Kaplan-Meier graphs for the Disease
Specific Survival, DSS, (panel a), for the Local Control
(panel b) and for the Loco-regional Control (panel c) for
the two groups of patients. No statistical significance was
observed in the difference between the groups. Median
Figure 1 Average DVH for the CTV, PTV and OARs for the two cohorts of patients.
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resulted of 52.8 ± 3.3 months (95% C.L.: 46.3-59.3) for RA
and 81.5 ± 5.3 months (95% C.L.: 71.0-91.9) for CRT. DSS
at 2 years was: 85.7% and 91.3% for CRT and RA and DSS
at 5 years was: 85.7% and 81.2% (at 59 months for RA)
respectively.
Five years Loco-regional control was of 78.1% and
82.1% for RA and CRT respectively. Complete response
was achieved in 54 patients (24 and 30 in the CRT and
RA groups respectively); 90.7% of these received CH-RT.
All HPV patients achieved complete response. All but
one HIV positive patients obtained complete response.
This case was treated with CRT and presented both local
and regional relapse. Local failure was observed in 3
patients per group (10.7% for CRT and 8.3% for RA);
regional failure in 4 patients per group (14.3% and 11.1%
respectively); distant failure was observed in 3 patients for
CRT (10.7%) and in 2 patients for RA (5.6%). Abdomino-
perineal resection (APR) was necessary in 3 patients
presenting with local failure after CH-RT.
Three of the CRT patients had local relapse associated
with regional relapse. In the group of patients treated
with RA, one achieved a partial response and requiredan abdominal resection 3 months after completion of
radio-therapy. Three further patients had local relapse,
associated with regional relapse in two cases. In other
2 patients there was regional failure without local
relapse. One patient experienced abdominal lymph-
adenopathy and liver metastases without local and
regional relapse.
Toxicity
Table 3 reports data for acute toxicity in the gastro-
intestinal (GI) and genitor-urinary (GU) tracts as well as
for the skin reactions. RA treatments lead to a reduction
of the absolute incidence of higher grade events. In fact,
grade 2–3 toxicity reduced of ~20% for GI (p = 0.06),
of ~6% for GU (but not statistically significant) and
of ~7% for the skin (with p = 0.05). Grade 1 toxicity
reduced of ~10% for GI. No grade 4 toxicity was
observed for any endpoint. Nevertheless, the distribu-
tions of toxicity across the therapy categories, resulted
the same on the basis of the results of the two inde-
pendent samples Mann–Whitney U test for the tree
domains. Specifically, p resulted 0.06, 0.3, 0.06 for the
GI, GU and skin toxicity distributions respectively.
Figure 2 Disease specific survival, local control and loco-regional control curves for the two cohorts of patients.
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Six patients had treatment break >3 days, 21% and 17%,
in both groups, 3D and VMAT respectively. Twenty
two CRT patients completed therapy without breaks
or <3 days versus thirty cases treated with VMAT.The reasons for all treatment break in our cases were:
gastrointestinal toxicity (8 cases in VMAT group and 6
in CRT group), dermatological toxicity (4 and 6 patients
in VMAT and CRT groups), genitourinary toxicity (1 and
2 patients in VMAT and CRT groups) or haematological
Table 3 Observed acute toxicity
CRT RA
n % n %
Gastro-intenstinal
G0 0 0 0 0
G1 3 10.7 11 30.6
G2 20 71.4 22 61.1
G3 5 17.9 3 8.3
G4 0 0 0 0
Genito-urinary
G0 8 28.6 16 44.4
G1 9 32.1 8 22.2
G2 11 39.3 12 33.3
G3 0 0 0 0
G4 0 0 0 0
Dermatologic
G0 0 0 0 0
G1 5 17.9 9 25
G2 12 42.8 22 61.1
G3 11 39.3 5 13.9
G4 0 0 0 0
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were found in treatment breaks.
Late toxicity was scored as follows: 5/36 (14%) and
3/36 (8%) patients had GI toxicity of grade 1 and grade
2 respectively in the RA group. This was observed in
1/28 (4%) and 4/28 (14%) in the CRT group. GU late
toxicity was observed only in 4/28 (14%) patients of the
CRT group: 3/28 (11%) had G2 and 1/28 (4%) had G1.
Discussion
The effectiveness of chemo-radiation therapy for anal
cancer has been demonstrated by several randomized
trials [19-21]. The most recent trials [22,23] suggested
that CH-RT with FU and MMC should remain the
standard of care. However, concurrent chemo-radiation
is associated with relevant acute gastrointestinal, geni-
tourinary, dermatological toxicities when conventional
radiation therapy techniques are used.
Both the Long-Term Update of RTOG 98–11 Phase
III [24] and the ACT II trial [23] showed that toxic
effects during chemo-radiation were similar in the
mitomycin and cisplatin treatment groups. Grade 3–4
hematologic toxicity was more common in the mitomy-
cin group. The rate of acute non-hematologic grade 3
or 4 toxicity was 74% in both groups according to the
RTOG trial. As a consequence, prolonged treatment
breaks were necessary and have been shown to nega-
tively affect local control [25,26]. The data presented inthis study showed that treatment interruptions had no
significant impact on local control while in the study of
Graf [25] it was shown that patients with overall treat-
ment time >41 days had 5 yr LC of 58% versus 79% if
overall treatment time was <41 days (p = 0.04).
Recently, there has been increasing attention on the
use of IMRT. Bazan [4] and Choung [6] directly com-
pared IMRT to CRT. In both series the use of IMRT was
associated with decreased toxicity and a consequent
reduction in the treatment breaks. Dasgupta [3] focused
on the outcomes of IMRT versus CRT and the results
demonstrated that in particular LRC was not compro-
mised by more conformal radiotherapy.
In the present study, 64 consecutive patients were
evaluated after treatment with radiotherapy alone or
concurrent chemotherapy with CRT or VMAT. Tumor
characteristics were similar in both groups. In the
VMAT group, one patient had stage IV at diagnosis with
single liver metastases. This patient was treated neoadju-
vantly with a combination of cisplatin and fluorouracil
[27,28] chemotherapy. After 6 cycles of systemic therapy
at completed response, the patient was enrolled for
definitive radio-chemotherapy with fluorouracil and
mytomicin regimen [19,22].
Our study had a median follow-up of 68.5 months
(range 6–93) and 19.0 months (range 7–59) for CRT and
VMAT groups respectively, in line with the previously
reported studies. Although the median follow-up for the
VMAT cohort was shorter, the rates of higher grade tox-
icities were lower than among the CRT cohort.
There might be some potential factors to consider in
addition: the different prescription doses in the two groups
and the different chemotherapy regimens followed. These
might obviously contribute to the different toxicity profiles
observed in the data. In addition, in a retrospective
analysis, toxicity reports tend to be inferior than what
achieved from prospective investigations.
Three HIV positive patients were treated with CRT and
3 with VMAT while two HPV positive cases underwent
CRTand one patient VMAT RA. Both HIV and HPV posi-
tive cases had comparable acute and late toxicity versus
non HIV/HPV patients. Albeit this study is limited by low
patient numbers, its results support previous findings that
high-dose EBRT in HIV-positive patients has durable
biochemical control with limited toxicity in line with
that of non–HIV-positive patients [29].
Analyzing the PTV coverage, the data resulted com-
parable between the two techniques, but the normal
healthy tissue sparing was more pronounced in the
VMAT plans, in particular for the bladder, the external
genitalia and the femoral heads.
Survival data are similar to earlier studies [3,4,7,10].
Our cohort treated with VMAT had a DSS at 2 yrs, LCC
and LRC rates of 85.7%, 86.3% and 78.1% respectively
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89.1% of LCC and 82.1% of LRC.
Although VMAT does not appear to improve the sur-
vival outcomes comparing to the CRT, its advantage is
principally the reduction of the severe RT-related toxicity.
The future prospective should consider dose–escalation
strategies to improve the disease-related outcomes.
Conclusion
The treatment of anal carcinoma patients with VMAT
(RapidArc) was evaluated in a retrospective comparison
against conformal therapy and resulted in the same
disease specific survival and loco or loco-regional
control. Improved profiles of toxicity were observed
for the patients treated with RapidArc.
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